Plain-English translation of NCT06819566 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a preventive procedure called endoscopic variceal ligation (EVL) can protect people with liver cancer from dangerous bleeding before they start treatment with atezolizumab plus bevacizumab. The procedure seals weak blood vessels in the esophagus that are at high risk of bleeding. The goal is to keep patients safe and able to continue their cancer treatment without interruption.
People receiving this medication have a higher risk of life-threatening bleeding from these weak vessels in the esophagus. If bleeding happens, it can force doctors to pause or stop cancer treatment, which reduces the chance the medication will work well. This trial is testing whether treating these vessels before starting the medication can prevent that serious complication.
You likely qualify if…
You likely don't qualify if…
You will first receive the preventive endoscopic procedure (EVL) within two weeks before starting your cancer medication. This involves a specialist passing a thin camera down your throat to locate and treat the weak blood vessels by placing small rubber bands around them. After this procedure, you will begin your cancer treatment and have follow-up endoscopies to monitor how well the procedure worked and whether the vessels have healed properly.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
South Korea